Identification of Successful Cognitive Aging in the Alzheimer’s Disease Neuroimaging Initiative Study

Feng V. Lin\textsuperscript{a,b,c,d,*}, Xixi Wang\textsuperscript{c,e}, Rachel Wu\textsuperscript{f}, George W. Rebok\textsuperscript{g}, Benjamin P. Chapman\textsuperscript{b,h} and the Alzheimer’s Disease Neuroimaging Initiative\textsuperscript{1}

\textsuperscript{a}School of Nursing, University of Rochester Medical Center, Rochester, NY, USA
\textsuperscript{b}Department of Psychiatry, University of Rochester Medical Center, Rochester, NY, USA
\textsuperscript{c}Department of Brain and Cognitive Science, University of Rochester, Rochester, NY, USA
\textsuperscript{d}Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, USA
\textsuperscript{e}Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA
\textsuperscript{f}Department of Psychology, University of California, Riverside, Riverside, CA, USA
\textsuperscript{g}Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
\textsuperscript{h}Department of Public Health Science, University of Rochester Medical Center, Rochester, NY, USA

Accepted 20 April 2017

Abstract. The present prospective observational study aimed to identify the existence of successful cognitive agers among a group of well-defined cognitively healthy older adults (\(n=354\), mean age = 75 years), and to examine baseline individual-level predictors and associated health outcomes over time. Episodic memory (EM) and executive function (EF) composite scores and multiple health outcomes were obtained annually over 5 years. Potential individual-level predictors that were related to Alzheimer’s disease pathology or genetic risk, neurodegeneration, and vascular risks were collected at baseline. Three latent classes with matched age and education were identified using growth mixture modeling: a group of participants who exhibited high, stable EM and EF (40.7\% of the sample, “successful agers”); a group who had initial high cognitive performance that declined over time (21.2\%, “declining agers”); and a group who had normal (EM) or poor (EF) but stable cognitive performance over time (38.1\%, “low stable agers”). The group classification predicted significant differences in the incidence of global cognitive impairment, the development of at least one depressive symptom, and everyday functional impairment. Sex, apolipoprotein E allele 4, amyloid-\(\beta_{1-42}\), and t-tau significantly contributed to the difference in cognitive trajectories between the successful agers and the other two groups. Characterizing successful cognitive agers who are relatively resistant to both tau and amyloid pathology provides potential pathways for promoting successful cognitive aging and preventing cognitive decline.

Keywords: Amyloid-\(\beta\), episodic memory, executive function, successful cognitive aging, tau

\textsuperscript{1}Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

*Correspondence to: Feng Vankee Lin, PhD, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14618, USA. Tel.: +1 585 276 6002; Fax: +1 585 273 1258; E-mail: vankee_lin@urmc.rochester.edu.
INTRODUCTION

Historically, cognitive decline was largely believed to be inevitable in the aging process and accelerated in neurodegenerative diseases, such as Alzheimer’s disease (AD) [1, 2]. Recent literature, however, suggests that there is inter-individual variability in the maintenance of cognitive capacities in old age [3–5]. Some older adults have superior cognitive capacities compared to age- and education-matched cognitively normal older adults [6, 7] or even when compared to cognitively normal younger or middle-age individuals [8–11]. Some retain excellent cognitive capacities over decades [12–14]. These emerging studies encourage more research to better understand the nature of “successful cognitive aging” or even so-called “Supernormals” [6, 7] or “Superagers” [9].

There are two issues regarding the identification of older adults exhibiting successful cognitive aging. First, most of the existing studies (although see [12, 15, 16]) identify excellent cognitive capacities via a brief screening for global cognition or a single domain, such as episodic memory (EM). Differing degrees of change across different cognitive domains are known in the aging process. For example, global cognition usually declines slower than specific cognitive domains because older adults can compensate for global cognitive loss via multiple factors [17–19]. Moreover, decline in EM and executive function (EF), two important cognitive abilities, may have different roles in AD pathology versus normal aging-related neurodegeneration that EM may be more sensitive to AD while EF may be more relevant to aging [20–23].

Other studies have developed composite scores that incorporating multiple cognitive domains [15], ignoring the fact that the longitudinal trajectories of these cognitive domains may not be identical. Morack et al. demonstrated longitudinal changes in multiple domains of psychological functioning to better understand successful aging, based on social integration, depression, and a single cognitive domain, memory [24]. A comprehensive understanding of multiple cognitive domains, especially their longitudinal trajectories, is required to more accurately characterize successful cognitive aging [12, 15, 16].

Second, factors prospectively predicting successful cognitive aging have mostly been socio-demographic characteristics rather than neurobiological characteristics, namely younger age and higher education, or behaviors, such as more engagement in physically or mentally stimulating activities (e.g., [18]). More recent cross-sectional case-control studies have started identifying neurobiological mechanisms related to successful cognitive aging. These studies suggest that differences in brain structure and function, especially in the cingulate cortex, prefrontal cortex, and medial temporal lobe, may be related to differences in cognitive abilities ranging from above average to deficient [6, 8, 11]. However, it is unclear if these neurobiological differences are due to aging-associated neurodegeneration or to AD-specific pathology. In our recent work, we found that older adults with excellent EM had less AD pathology, indexed by whole-brain cerebral amyloid deposition [6]. These aging adults also were less affected by aging-associated neurodegeneration indexed by a network promoting increased nitric oxide bioavailability [7]. An important issue is that these results emerged from case-control studies, and a clarification of the prospective roles of these critical neurobiological factors in predicting successful cognitive aging is required for identifying proper therapeutic targets.

The present study applied growth mixture models that examined the potentially heterogeneous longitudinal trajectories of multiple cognitive domains simultaneously. This procedure is known as “finite mixture modeling” (FMM) [25–27]. Here, we aimed to identify the existence of a successful cognitive aging group among a sample of well-defined cognitively healthy aging adults. Using FMM, we first characterized the trajectories of EM and EF developed using composite scores of multiple cognitive battery tests respectively over a 5-year span among cognitively healthy older adults. We also examined baseline individual-level profiles that could predict the heterogeneity in the trajectories, including neurodegeneration (may be due to aging, AD, or other neurologic disorders) and factors specific to AD (pathology or genetic risk). Lastly, we distinguished the trajectories’ influence on the incidence of aging or AD-associated adverse health outcomes (i.e., global cognitive, emotional, and functional impairments) over time.

METHODS

Data source

The data used in the preparation of this article were obtained from the ADNI database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, M.D. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment and early AD. For up-to-date information, see http://www.adni-info.org.

Participants

The data used in this study were obtained from ADNIGO and ADNI2 datasets, which included multiple pathological and clinical assessments. To identify the existence of a successful cognitive aging group among a group of well-defined cognitively healthy aging adults, we firstly identified 354 subjects who had both EM and EF composite scores (described in the “Measures” section) and were characterized as being free from cognitive impairment (e.g., any types of dementia, mild cognitive impairment) and major psychiatric disorders (e.g., major depression) during the period of their participation in the study. Other inclusion criteria include: Mini-Mental State Exam score 24–30, Clinical Dementia Rating global score = 0, education adjusted scores on delayed recall of one paragraph from Wechsler Memory Scale Logical Memory II >8 for 16 or more years of education, >4 for 8–15 years of education, and >2 for 0–7 years of education.

Measures

EM and EF were two composite scores derived from multiple measures assessed annually over 5 years (from baseline to a 4-year follow-up). Crane et al. [28] and Gibbons et al. [29] developed the two composite scores using separate factor analyses. Because they were derived using a factor analysis, the composite scores are based on the most intercorrelated tests in the battery, and therefore represent the most internally consistent test groupings. The composite EM index was based on the memory-related domains of the Mini-Mental Status Examination, Alzheimer’s Disease Assessment Scale-Cognition subscale, Rey Auditory Verbal Learning Test, and Logical Memory test. The composite EF index was based on the Wechsler Memory Scale- Revised Digit Span Test, Digit Span Backwards, Category Fluency-animals and vegetables, Trails A and B, and the Clock Drawing Test. Of note, all of these individual tests are performance-based standard clinical neuropsychological tests. The average standardized EM and EF composite score is 0 among the entire ADNI sample (including those with cognitive impairment). EM and/or EF score above 0 indicated having relatively intact performance. In addition, the mean of the EM score for cognitively healthy participants in ADNI was 1.0, and for EF was 0.70 [28, 29]. Before conducting the FMM analysis, correlations between EM and EF were examined with linear regressions for each individual visit. After controlling for age and education, only 14.0–26.8% of the variance in EM was explained by EF across all assessments. This result means that heterogeneity might exist between EM and EF measures, indicating the appropriateness to apply FMM for determining latent classes.

Baseline individual characteristics included cerebrospinal fluid and genetic markers related to neurodegeneration, AD, and vascular risk factors for dementia. Amyloid-β (1-42) (Aβ1-42) and t-tau were derived from the cerebrospinal fluid aliquots, measured using the multiplex xMAP Luminex platform (Luminex Corp., Austin, Tex., USA) with immunoassay kit-based reagents (INNO-BIA AlzBio3; Innogenetics, Ghent, Belgium). Details regarding the immunoassay reagents and analytical platform are included in [30]. Based on the aging and AD literature, the Aβ1-42 cutoff value ≤180 pg/ml was used to define a positive AD pathology, and a t-tau cutoff value ≥96 pg/ml was used to define positive neurodegeneration [31–33]. An apolipoprotein E allele 4 (APOE4) carrier was defined as having at least one APOE4 allele (by analyzing blood samples at the National Cell Repository for AD), which is the primary genetic risk factor for late-onset AD [34]. Obesity was defined as body mass index ≥30, and hypertension was defined as systolic blood pressure ≥150 and/or diastolic pressure ≥90. In addition, participants’ demographics, collected at baseline, were included in the analyses. Baseline sample characteristics are included in Table 1.

Health outcomes were measured annually from baseline up to a 4-year follow-up, corresponding to the time points available for the EM and EF measures. Global cognition was measured using the Montreal Cognitive Assessment (MOCA; [35]). We used the MOCA as an index for global cognition, since it was not included in the development of EM and EF composite scores. Impaired global cognition was defined as MOCA <26 [35]. Depressive symptoms were measured using the 15-item Geriatric Depressive Scale (GDS; [36]). Given the skewness of the data distribution, a score greater than 0 was identified as positive for depressive symptoms. Everyday
cognition was measured using the Everyday Cognition (ECog) scale, which is a self-reported measure [37]. Participants were asked to rate their performance on a variety of everyday activities related to different domains of cognition, indicating how much they perceived their performance to have changed over the past 10 years. Scores on each item ranged from 1 (no change over 10 years) to 4 (much worse performance); a score of 5 indicated that the participant did not know the answer [37]. We averaged all items excluding any item scored as a “5”. Lower scores indicated better perceived functioning. We defined ECog $\geq 2$ as having deficits in everyday cognition. Everyday functioning was measured using the Pfeffer Functional Activities Questionnaire (FAQ; [38]), including 10 self-reported items of instrumental activities of daily living. Scores on each item ranged from 0 (normal) to 3 (dependent). A sum score was developed based on all items. We defined FAQ $>0$ as having deficits in everyday functioning. Of note, due to an extremely healthy aging sample, we used a high threshold to define the presence of a symptom or deficit, instead of the traditional clinical diagnostic criteria (e.g., <1% of the current sample had GDS $>5$, which indicates potentially major depressive symptoms).

Data analyses

An FMM was conducted using R, while other analyses were conducted using IBM SPSS 22.0. A bivariate FMM analyzed the EM and EF longitudinal trajectories using the R package, “FlexMix” [27]. An FFM was justified for the EM and EF longitudinal data, because a multi-modal distribution was observed for the variables. In addition, the present sample was not assigned into groups [27, 39]. FMM employed a generalized estimating equation model of the longitudinal performance of EM and EF with an M-dependent working correlation matrix for the multiple time points. Parametric bootstrapping was used to analyze the reliability, or variability, of coefficient estimates in the FMM to determine the solutions [40]. Age and education, the two primary confounders for cognitive aging, were controlled in the analysis. The best fitting model was decided with the bias-corrected Akaike Information Criterion (AICc), the Bayesian Information Criterion (BIC), and the negative Log-likelihood, in conjunction with considerations of theoretical utility. Smaller values in these criteria indicated better model fit. Maximum posterior probability was then used to segment participants into classes after deciding the best fitting model. In the present study, we found the 3-class solution to be the best solution after running up to 5-class solutions. Since we aimed at characterizing the group with successful cognitive aging, in the following analyses, class 2 (the best performing class over time, potentially reflecting successful cognitive aging) from the 3-class solution was considered the reference class, comparing to other classes. Predictors of latent class membership from the FMM were determined using a multinomial logistic regression. The baseline participant characteristics were analyzed separately as predictors to avoid any interacting effect among these variables. However, when examining factors related to vascular risk, AD, and neurodegeneration, we controlled for sex. The impact of latent class on the incidence of adverse health outcomes was examined using the Cox Proportional Hazard Regression. We used time since baseline as the timescale to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident adverse health outcomes. Two methods (i.e., visual inspection of log minus log survival curves, and test of Schoenfeld residuals) were used to verify the proportional hazard assumptions. All tests were two-tailed, and significance was considered at a $p$ value less than 0.05.

RESULTS

Classification of EM and EF

We examined the number of classes from one (parsimonious) to five (overfitting) to determine the best fitting model. After controlling for age and education, the 3-class solution was the best fitting model as
Table 2
Model fit for the classification

<table>
<thead>
<tr>
<th>Model fit indicators</th>
<th>One-class model</th>
<th>Two-class model</th>
<th>Three-class model</th>
<th>Four-class model</th>
<th>Five-class model</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICc</td>
<td>2,747.52</td>
<td>2,665.14</td>
<td>2,630.39</td>
<td>2,668.02</td>
<td>2,664.44</td>
</tr>
<tr>
<td>BIC</td>
<td>2,757.43</td>
<td>2,675.05</td>
<td>2,640.30</td>
<td>2,677.94</td>
<td>2,674.36</td>
</tr>
<tr>
<td>Negative Log-likelihood</td>
<td>1,371.75</td>
<td>1,330.57</td>
<td>1,313.19</td>
<td>1,332.01</td>
<td>1,330.22</td>
</tr>
</tbody>
</table>

Table 3
Parameter estimates of classification for EM and EF

<table>
<thead>
<tr>
<th>Class</th>
<th>N (%)</th>
<th>Intercept (SE)</th>
<th>Slope (SE)</th>
<th>Intercept (SE)</th>
<th>Slope (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>75 (21.2)</td>
<td>1.41 (0.08)**</td>
<td>-0.05 (0.02)**</td>
<td>1.25 (0.08)**</td>
<td>-0.14 (0.02)**</td>
</tr>
<tr>
<td>2</td>
<td>144 (40.7)</td>
<td>1.51 (0.06)**</td>
<td>0.003 (0.02)</td>
<td>1.05 (0.08)**</td>
<td>0.08 (0.02)**</td>
</tr>
<tr>
<td>3</td>
<td>135 (38.1)</td>
<td>1.08 (0.20)**</td>
<td>-0.12 (0.07)</td>
<td>0.40 (0.07)**</td>
<td>-0.06 (0.02)**</td>
</tr>
</tbody>
</table>

**p < 0.005; ***p < 0.001. ADNI cognitively normal cohort mean EM = 1.0, mean EF = 0.7.

Fig. 1. The trajectories of EM and EF from baseline to a 4-year follow-up by the latent class. EM, episodic memory; EF, executive function; bsl, baseline.

indicated by the lowest AICc, BIC, and negative Log-likelihood (Table 2). Table 3 displays the intercepts and slopes of EM and EF in each class with the 3-class solution. Figure 1 shows the trajectories of EM and EF from baseline to a 4-year follow-up. Compared to the cutoff for cognitive normal as mean Z-score for EM (at 1.0) and EF (at 0.7) in ADNI [28, 29], participants in Class 1 (21.2%) had relatively high EM and EF that both declined significantly over time; those in Class 2 (40.7%) had relatively high EM remained stable over time and relatively high EF that increased significantly over time; and those in Class 3 (38.1%) had average stable EM and low EF that declined significantly over time (see Table 3).
Baseline sample characteristics in predicting class membership

Table 4 shows the baseline characteristics in predicting class membership using the multinomial logistic regression, with Class 2 as the reference group. Males were more likely to be in Class 3 (OR = 2.18, 95%CI: 1.35–3.53) than Class 2 (and at trend level, compared to Class 1). Therefore, sex was controlled when analyzing other baseline characteristics. APOE4 carriers (OR = 2.16, 95%CI: 1.26–3.72) and Aβ₁₋₄₂+ (OR = 2.33, 95%CI: 1.29–4.21) were more likely to be in Class 3 compared to Class 2. Individuals with t-tau+ was more likely to appear in Class 1 (OR = 2.47, 95%CI: 1.02–6.01) compared to Class 2. Neither obesity nor hypertension was a significant predictor.

Incidence of adverse health outcomes over time by latent class

Table 5 and Fig. 2 show the impact of the latent class on the incident adverse outcomes using a Cox regression. Both Class 1 (HR = 1.30, 95%CI: 1.00–1.68) and Class 3 (HR = 2.53, 95%CI: 2.04–3.13) had a higher likelihood of developing at least one depressive symptom (GDS >0) (HR = 1.40, 95%CI: 1.15–1.71), perceptions of everyday cognition deficits (Ecog ≥2, HR = 2.34, 95%CI: 1.39–3.93), and IADL deficits (FAQ >0, HR = 1.83, 95%CI: 1.10–2.42).

DISCUSSION

Applying the FMM to a 5-year prospective cognitively healthy aging cohort with a mean age of 75 years, we were able to distinguish a group of “successful” cognitive agers who exhibited high, stable EM and EF (40.7% of the sample, “successful agers”) from their age- and education-matched counterparts, who either had initially high cognitive performance that declined over time (21.2%, “declining ager”) or had normal and stable (EM) or poor (EF) cognitive performance over time (38.1%, “low stable ager”). The group classification predicted differences in the incidence of global cognitive impairment, the development of at least 1 depressive symptom, and IADL impairment. In addition to sex, both AD pathology (Aβ₁₋₄₂) or genetic risk factor for AD (APOE4), and neurodegeneration (t-tau) contributed to the difference in cognitive trajectories between successful agers and the other two groups.

Although the maintenance of any level of earlier life cognitive functioning (even if poor) might
be defined as “successful,” the “successful agers” in this study were those who exhibited above average cognitive functioning without decrement over time. The proportion of successful cognitive agers (at 35.8%) is slightly higher than those reported in larger community-dwelling aging studies of successful agers. Previous studies on successful aging have not used any latent class analysis to classify successful cognitive aging (see meta-analysis [41]). In addition to using FMM to identify this successful ager group, the slightly higher proportion in our study may due to the less diverse sampling procedures from ADNI study. As a longitudinal study with a commitment to intense biological assessments, ADNI may have already preselected a relatively healthy group of normal controls. Therefore, the findings may not be as applicable to other aging populations.

Regardless, both the cognitive domains and trajectories involved in characterizing successful cognitive agers warrant discussion. We incorporated a broad assessment of EF (visuospatial, attention, working memory, and verbal fluency) into the measures of cognitive functioning in the present study. EM has been the most frequently used determiner of successful cognitive aging in the literature [6, 7]. However, individuals with excellent EM do not necessarily have equivalent EF [7]. EF is involved in almost every aspect of emotional and functional health in older adults’ everyday life (e.g., [26]). Perhaps because of the involvement of EF, the latent class here significantly predicted later functional, depressive, and global cognitive impairment.

The trajectory, including the intercept (baseline level) and slope (rate of change over time), contributed to determining which individuals were
successful cognitive agers. The successful agers remained relatively stable in EM over time, and some even had significant improvement in EF. The apparent improvement of EF may be explained by practice effects related to the specific tasks, which were not controlled for in the development of the Z-scores in each domain. Yet, practice effects themselves are evidence of cognitive astuteness, as they are related to learning and retention, a prominent component of successful aging from the older adult’s perspective [42, 43] and a unique phenomenon for Class 2 (“successful agers”) here. Conversely, the declining agers had baseline levels of EM and EF comparable to the successful agers, although both domains declined significantly over time. This group may often be categorized into successful agers in cross-sectional studies, while in reality this group may encounter multiple factors that affect the longitudinal trajectory. Lastly, for “low stable agers”, the baseline levels of EM and EF were averaged or relatively low, and EF declined slightly over time. Of note, the true value of the EM slope for this group was large (~0.12 unit change per year). Therefore, the non-significant change over time in the “low stable agers” may have resulted from the large intra-individual variability of the slope within this group (SE = 0.07 of EM slope in Class 3 compared to SE = 0.02 for the EM slopes in the other classes).

In the present study, two novel characteristics of the “successful agers” emerged by comparing them to the other two groups: they started with both less neurodegeneration and AD pathology/genetic risk. Compared to the “successful agers”, the “declining agers” had a significantly higher prevalence of t-tau+ at baseline compared to the successful agers. t-tau+, a marker for neurodegeneration may have a broad influence on multiple cognitive domains associated with normal aging [32]. Aligned with the predictor of t-tau, the “declining agers” possibly reflect a normal aging associated cognitive declining trajectories, as shown in other cohort studies [26]. By contrast, for the low stable agers, their relatively poor baseline cognitive performance and trajectories were more relevant to APOE4 and Aβ1-42+, both of which are related to pathophysiology or genetic risk of AD. Importantly, all members of this class had a normal cognitive status. Considering the factors that seem to influence their cognitive trajectories, this group may include individuals with preclinical AD [44], and have a risk for incident dementia [21]. Furthermore, we acknowledge that cerebrospinal fluid t-tau may not directly represent brain pathology compared to the same measure of Aβ1-42 (see [45]). The dissociated patterns between t-tau versus Aβ1-42 (or APOE4) in predicting cognitive trajectories in cognitively healthy older adults revealed in the current study needs to be replicated. Regardless, given the higher prevalence of AD pathology/genetic risk and neurodegeneration, and longitudinally more adverse health consequences in multiple domains compared to the successful agers, the declining agers and low stable agers may warrant clinical attention early on.

We purposely controlled for age and education when determining the latent classes since we were interested in the true effect of the other factors that were distinct from these two unmodifiable but major factors of cognitive aging. Also, controlling for these two factors may have helped remove the shared similarity between EM and EF, which may have helped identify distinctive trajectories for these typically correlated domains. Other individual level characteristics differentiating the classes need some discussion here. First, health history, such as hypertension and obesity, had small effects on this aging sample’s classification. Of note, previous studies have found that when health history (e.g., blood pressure, body mass index) was a significant predictor for successful aging, the criteria for successful aging usually relied on physical domains [46]. Second, there were more males in the declining and low stable ager groups, compared to the successful ager group. Previous studies have suggested that males have a higher risk for developing cognitive decline [47].

There are some limitations and relevant future directions for this research. First, recent studies comparing successful agers with cognitively intact or impaired counterparts have characterizing individuals with excellent memory capacity via structural and functional neuroimaging profiles seeded in the cingulate cortex [6, 8]. Given the relatively small sample size of neuroimaging data available in the current study (about a tenth of the whole sample), we did not examine the neuroimaging profiles in the current dataset. Whether including EF in the operational definition of successful cognitive aging would change the existing understanding of structural or functional imaging profile. In particular, future work should provide a comprehensive comparison of imaging profiles related to AD pathology versus neurodegeneration in relation to successful cognitive aging. Second, as stated earlier, we defined health outcomes (e.g., free of depressive symptoms) using our own restricted criteria, since the dataset contained an extremely healthy aging sample. Future studies may need to reexamine
the relationships between health outcomes and successful cognitive aging using clinically meaningful cutoff scores for health outcomes. Third, we did not assess any cognitive lifestyle factors (e.g., engagement in stimulating leisure activities) that may help explain why cognitive abilities increase in the successful aging group, especially among women. A next step could examine the interaction between pathological and everyday cognitive activities influencing successful cognitive aging.

ACKNOWLEDGMENTS

The writing of this manuscript was supported by the Furth Fund from the University of Rochester to F. Lin.

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Authors’ disclosures available online (http://j-alz.com/manuscript-disclosures/16-1278r3).

REFERENCES


